Callisto Pharmaceuticals, Inc. (“KAL”, Amex) announced today that Gary Jacob, Ph.D., Callisto’s CEO and CSO, is scheduled to present on Monday, May 14, 2007 at 10:05 a.m. Central European Time in the Atlantique Salon – Western during the Acumen Biofin Rodman & Renshaw 4th Annual Global Healthcare Conference. The conference is being held at Le…
Independent German Based Equity Research Firm Maintains Buy Rating and $2.00 per share price target NEW YORK, April 24 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments for cancer and inflammatory diseases, announced that a leading independent research firm, First Berlin Equity Research, has issued an updated research…
NEW YORK, April 24 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments for cancer and inflammatory diseases, announced that Rodman and Renshaw has issued a research report with a “Market Outperform” rating and a price target of $3.00 per share. About Rodman and Renshaw Rodman & Renshaw, LLC…
Company Cites Progress with Clinical and Preclinical Programs NEW YORK, April 16 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (AMEX: KAL), a developer of new drug treatments in the fight against cancer and other major health threats, provided an update covering its strategic and drug development activities for the period of 2006 and first quarter of 2007….
NEW YORK, April 11 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (AMEX: KAL)(FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today the publication of a research article on Atiprimod, Callisto’s drug currently in clinical trials in carcinoid cancer and multiple myeloma patients, in the February 2007…
NEW YORK, April 5 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (AMEX: KAL), a developer of new drug treatments in the fight against cancer and other major health threats, announced today additional data confirming efficacy of Guanilib, a first-in-class compound currently being developed for the treatment of inflammatory bowel disease (IBD), in two different standard animal models…
Multi-Institutional Trial Utilizes POETIC Consortium of Ten Institutions with First Clinical Sites Opened at the Phoenix Children’s Hospital and the University of Arizona NEW YORK, Feb. 22 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (AMEX: KAL)(Frankfurt”>CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today the opening of…
NEW YORK, Feb. 9 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (AMEX: KAL)(Frankfurt”>CA4), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat cancer and GI inflammatory diseases, today announced that Gary S. Jacob, Ph.D., CEO and CSO, will discuss the Company’s oncology drug development programs and provide a general corporate overview at…
NEW YORK, Jan. 31 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (AMEX: KAL), a developer of new drug treatments in the fight against cancer and other major health threats, announced today the opening of a second clinical site, the Dana-Farber Cancer Institute in Boston, MA, for its Phase II clinical trial of Atiprimod to treat low to…
NEW YORK, Jan. 25 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (AMEX: KAL)(Frankfurt”>CA4), a biopharmaceutical company primarily focused on the development of drugs to treat cancer and other major health threats, today announced acceptance of an abstract on Atiprimod, the Company’s anti-cancer drug candidate, to be presented at the 98th annual meeting of American Association of Cancer…